+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Regorafenib



Regorafenib



Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 201: 185-196



Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multikinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF). Regorafenib is the first small-molecule multikinase inhibitor to achieve survival benefits in metastatic colorectal cancer that has progressed after all standard therapies. Consequently, regorafenib was FDA approved for this indication. In addition, regorafenib treatment resulted in a significant improvement in progression-free survival (PFS) compared with placebo in patients with metastatic gastrointestinal stromal tumors (GIST) after progression on standard treatments and is also an FDA approved indication. Currently, regorafenib is examined in several clinical trials (mostly phase II) in different tumor entities, including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and soft tissue sarcoma (STS).

(PDF emailed within 1 workday: $29.90)

Accession: 055446594

Download citation: RISBibTeXText

PMID: 24756792


Related references

Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice. Clinical and Translational Science 2019, 2019

Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biology and Therapy 16(12): 1710-1719, 2016

Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. European Journal of Cancer 99: 28-36, 2018

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study. South Asian Journal of Cancer 8(1): 22-26, 2019

Regorafenib. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 211: 45-56, 2018

RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw. Journal of the National Cancer Institute 108(9): -, 2016

Regorafenib for cancer. Expert Opinion on Investigational Drugs 21(6): 879-889, 2012

A closer look at regorafenib. Clinical Advances in Hematology & Oncology 16(10): 667-669, 2018

Regorafenib: Dress. Prescrire International 24(156): 20-21, 2015

Regorafenib- associated panniculitis. Dermatology Online Journal 22(6), 2017

Regorafenib Also Can Cause Osteonecrosis of the Jaw. Journal of the National Cancer Institute 108(4), 2016

Regorafenib: start low and go slow. Targeted Oncology 10(3): 445-447, 2016

Regorafenib in gastric cancer. Translational Gastroenterology and Hepatology 2: 16, 2017

Regorafenib use as a possible cause of intestinal perforation. Acta Oncologica 52(8): 1789-1790, 2014

Intestinal perforation after regorafenib usage. Turkish Journal of Gastroenterology 29(2): 245-247, 2018